DE69633717T2 - Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis - Google Patents

Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis Download PDF

Info

Publication number
DE69633717T2
DE69633717T2 DE69633717T DE69633717T DE69633717T2 DE 69633717 T2 DE69633717 T2 DE 69633717T2 DE 69633717 T DE69633717 T DE 69633717T DE 69633717 T DE69633717 T DE 69633717T DE 69633717 T2 DE69633717 T2 DE 69633717T2
Authority
DE
Germany
Prior art keywords
mab
monoclonal antibody
psoriasis
ior
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633717T
Other languages
German (de)
English (en)
Other versions
DE69633717D1 (de
Inventor
Jose Enrique La Lisa MONTERO CASIMIRO
Josefa 10 de Octubre LOMBARDERO VALLADARES
Rolando 10 de Octubre PEREZ RODRIGUEZ
Patricia Sierra Blazquez
Blanca Rosa La Lisa TORMO BRAVO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Publication of DE69633717D1 publication Critical patent/DE69633717D1/de
Application granted granted Critical
Publication of DE69633717T2 publication Critical patent/DE69633717T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69633717T 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis Expired - Lifetime DE69633717T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CU12095 1995-11-17
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones

Publications (2)

Publication Number Publication Date
DE69633717D1 DE69633717D1 (de) 2004-12-02
DE69633717T2 true DE69633717T2 (de) 2006-02-02

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633717T Expired - Lifetime DE69633717T2 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis

Country Status (15)

Country Link
US (1) US6572857B1 (https=)
EP (1) EP0807125B1 (https=)
JP (1) JP4113929B2 (https=)
KR (1) KR100533854B1 (https=)
CN (1) CN1222540C (https=)
AT (1) ATE280783T1 (https=)
AU (1) AU722882B2 (https=)
BR (1) BRPI9607171B1 (https=)
CA (1) CA2210751C (https=)
CU (1) CU22584A1 (https=)
DE (1) DE69633717T2 (https=)
DK (1) DK0807125T3 (https=)
ES (1) ES2231826T3 (https=)
PT (1) PT807125E (https=)
WO (1) WO1997019111A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20070003568A1 (en) 2003-02-24 2007-01-04 Alice Dautry-Varsat Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
PT2119452T (pt) * 2006-12-26 2020-05-08 Ct Inmunologia Molecular Composição farmacêutica que compreende um anticorpo monoclonal anti-cd6 utilizado no diagnóstico e tratamento de artrite reumatoide
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
JP5511684B2 (ja) 2008-01-11 2014-06-04 アドヘロン セラピューティクス，インコーポレイテッド 炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト
EA201001467A1 (ru) * 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
US8940300B2 (en) * 2010-07-15 2015-01-27 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9910039B2 (en) 2011-07-01 2018-03-06 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
SG11202008149RA (en) 2018-02-27 2020-09-29 Equillium Inc Anti cd6 antibodies for treating severe asthma
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
MX2021010283A (es) 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2024534975A (ja) 2021-09-08 2024-09-26 セントロ ド インムノロジア モレキュラー 過剰炎症反応に起因する細胞および臓器の損傷の予防における抗ｃｄ６モノクローナル抗体の使用
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175247A1 (en) * 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
CA2210751C (en) 2007-01-30
CN1175957A (zh) 1998-03-11
ES2231826T3 (es) 2005-05-16
EP0807125A2 (en) 1997-11-19
DK0807125T3 (da) 2005-03-14
PT807125E (pt) 2005-03-31
AU7690596A (en) 1997-06-11
WO1997019111A2 (es) 1997-05-29
DE69633717D1 (de) 2004-12-02
CU22584A1 (es) 1999-11-03
WO1997019111A3 (es) 1998-02-12
US6572857B1 (en) 2003-06-03
BR9607171A (pt) 1997-11-11
KR19980701502A (ko) 1998-05-15
CN1222540C (zh) 2005-10-12
JPH11506017A (ja) 1999-06-02
JP4113929B2 (ja) 2008-07-09
KR100533854B1 (ko) 2006-09-20
MX9705445A (es) 1998-06-30
CA2210751A1 (en) 1997-05-29
AU722882B2 (en) 2000-08-10
ATE280783T1 (de) 2004-11-15
EP0807125B1 (en) 2004-10-27
BRPI9607171B1 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
DE69633717T2 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE3853636T3 (de) Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
DE69532940T2 (de) Verfahren zur Herstellung modifizierter Immunoglobuline mit verminderter Immunogenität der variablen Domänen eines Antikörpers der Maus, Zusammensetzungen, die diese enthalten
DE3854536T2 (de) Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
DE69535133T2 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
DE69925909T2 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE60038252T2 (de) Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
DE69117284T2 (de) Rekombinante antikörper gegen tnf-alpha
DE69637131T2 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
DE69231135T2 (de) CD2 bindender Bereich für das Lymphocyten-Funktion assoziierte Antigen-3
DE69535243T2 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DE3852374T2 (de) Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
DE69233204T2 (de) Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE69032662T2 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
DE69309906T2 (de) Behandlung für entzündungserkrankung des darmes
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
DE68923675T2 (de) Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
DE68921979T2 (de) Antikörper für die antilymphozyten-antikörpertherapie.
DE4134982A1 (de) Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
DE69029970T2 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
DE3889062T2 (de) Monoklonaler Antikörper gegen humanen BCDF.
EP0430193A1 (de) Monoklonale Antikörper und ihre Verwendung
DE69020112T2 (de) Spezifische bindende Wirkstoffe.
DE60005952T2 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition